Literature DB >> 26059925

Breast Cancer Survivorship: Where Are We Today?

Patricia A Ganz1, Pamela J Goodwin.   

Abstract

Breast cancer is the most common cancer in women, and survivors with this diagnosis account for almost one fourth of the over 14 million cancer survivors in the US. After several decades of basic and clinical trials research, we have learned much about the heterogeneity of breast cancer and have evolved a complex and multidisciplinary treatment approach to the disease. Increasingly, we are paying attention to the long term and late effects of breast cancer treatment, and this is largely the subject of this volume. In this chapter, the authors introduce the topic of breast cancer survivorship and highlight the organization and content of this volume, briefly describing the contents of the subsequent chapters.

Entities:  

Mesh:

Year:  2015        PMID: 26059925     DOI: 10.1007/978-3-319-16366-6_1

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  27 in total

1.  MicroRNA-765 alleviates the malignant progression of breast cancer via interacting with EZH1.

Authors:  Zhen Zeng; Yichen Yang; Hengyu Wu
Journal:  Am J Transl Res       Date:  2019-07-15       Impact factor: 4.060

2.  6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers.

Authors:  Hailing Yang; Zhang Shu; Yongying Jiang; Weiqun Mao; Lan Pang; Abena Redwood; Sabrina L Jeter-Jones; Nicholas B Jennings; Argentina Ornelas; Jinhua Zhou; Cristian Rodriguez-Aguayo; Geoffrey Bartholomeusz; LaKesla R Iles; Niki M Zacharias; Steven W Millward; Gabriel Lopez-Berestein; Xiao-Feng Le; Ahmed A Ahmed; Helen Piwnica-Worms; Anil K Sood; Robert C Bast; Zhen Lu
Journal:  Clin Cancer Res       Date:  2019-08-07       Impact factor: 12.531

3.  Downregulation of microRNA-30c-5p was responsible for cell migration and tumor metastasis via COTL1-mediated microfilament arrangement in breast cancer.

Authors:  Bei Pei; Tongyang Li; Qi Qian; Wenqiang Fan; Xiao He; Yulan Zhu; Lingyun Xu
Journal:  Gland Surg       Date:  2020-06

4.  Contribution of cost to treatment nonadherence in the US breast cancer survivors: a population-based analysis.

Authors:  Caiwei Zheng; Anees B Chagpar
Journal:  Breast Cancer Res Treat       Date:  2022-01-06       Impact factor: 4.872

5.  Upregulation of Cyclin B2 (CCNB2) in breast cancer contributes to the development of lymphovascular invasion.

Authors:  Abrar I Aljohani; Michael S Toss; Khloud A El-Sharawy; Sameer Mirza; Graham R Ball; Andrew R Green; Emad A Rakha
Journal:  Am J Cancer Res       Date:  2022-02-15       Impact factor: 6.166

6.  Association of GSTP1 p.Ile105Val (rs1695, c.313A > G) Variant with the Risk of Breast Carcinoma among Egyptian Women.

Authors:  Magdy M Youssef; Afaf M Elsaid; Rasha A El-Saeed; Riyadh T Mukhlif; Hisham Megahed; Adel I Al-Alawy; Rami M Elshazli
Journal:  Biochem Genet       Date:  2021-05-03       Impact factor: 1.890

7.  Pharmacists' knowledge, attitudes, beliefs, and barriers toward breast cancer health promotion: a cross-sectional study in the Palestinian territories.

Authors:  Ramzi Shawahna; Hiba Awawdeh
Journal:  BMC Health Serv Res       Date:  2021-05-06       Impact factor: 2.655

8.  Study on the Anticancer Effect of an Astragaloside- and Chlorogenic Acid-Containing Herbal Medicine (RLT-03) in Breast Cancer.

Authors:  Yanchu Li; Xianyong Li; Chen Cuiping; Rong Pu; Yin Weihua
Journal:  Evid Based Complement Alternat Med       Date:  2020-06-10       Impact factor: 2.629

9.  Assessment of Lymphovenous Anastomosis Patency: Technical Highlights.

Authors:  Antonio J Forte; Maria T Huayllani; Andrea Sisti; Daniel Boczar; Pedro Ciudad; Oscar J Manrique; Rudolf F Buntic
Journal:  Plast Reconstr Surg Glob Open       Date:  2020-03-27

10.  MiR-16-5p inhibits breast cancer by reducing AKT3 to restrain NF-κB pathway.

Authors:  Liwei Ruan; Xiaojun Qian
Journal:  Biosci Rep       Date:  2019-08-23       Impact factor: 3.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.